Pharmaceuticals

Dachser Air & Sea Logistics certified for pharmaceutical shipments on three continents

KEMPTEN, Germany, Nov. 1, 2019 /PRNewswire/ -- Following Frankfurt, Mumbai, and Hyderabad, Atlanta is now Dachser's fourth location to receive certification in ten months, further expanding the company's network services for its customers in the life science and healthcare sector.

2019-11-01 09:00 646

Mallinckrodt and Terumo BCT Announce UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for the Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults

SYDNEY, Nov. 1, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that UVADEX®  (methoxsalen) has received regulatory approval inAustralia by th...

2019-11-01 04:35 5538

Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA

GERMANTOWN, Maryland, Oct. 31, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (Nasdaq: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, will begin trading on the Nasdaq Capital Market under the ticker symbol, NASDAQ: SNCA beginning onN...

2019-10-31 23:00 4082

GC Pharma Reports Q3 2019 Results

YONGIN, South Korea, Oct. 30, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedSeptember 30, 2019. Key Figures Q3 2019(1) Growth(1) Total revenues K...

2019-10-30 21:00 5210

Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases

GERMANTOWN, Maryland, Oct. 30, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (fka Neuralstem, Inc.) (NASDAQ: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, and Jiangsu QYuns Therapeutics Co., Ltd., aChina-based company focused on m...

2019-10-30 19:00 3303

EC Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay

SAN DIEGO, Oct. 30, 2019 /PRNewswire/ -- Invivoscribe, Inc. announced today that the European Commission (EC) has approved the Astellas drug XOSPATA™  (gilteritinib) as a monotherapy for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) withFLT3 mutations (FL...

2019-10-30 18:00 354

Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit

GERMANTOWN, Maryland, Oct. 29, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (fka Neuralstem, Inc) (NASDAQ: CUR) a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, will present at the 7th China Renaissance Healthcare and Life Sciences Leaders...

2019-10-29 13:17 2559

European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Not intended for US, Canada and UK-based media  -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen approved across all IMDC prognosti...

2019-10-29 02:00 419

Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis

- ADVISE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ...

2019-10-28 20:30 2562

HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology Platform As A Drug Discovery Tool In Preclinical Studies For Nonalcoholic Steatohepatitis (NASH)

SINGAPORE, Oct. 28, 2019 /PRNewswire/ -- HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve quantifiable and reproducible...

2019-10-28 08:38 370

WuXi STA's Jinshan Facility Passes EMA Inspection

SHANGHAI, Oct. 28, 2019 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announced today that its Jinshan manufacturing facility inShanghai, China has successfully passed an inspection by the European Medicines Agency (EMA) with no critical and no major fin...

2019-10-28 08:00 389

HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology Platform As A Drug Discovery Tool In Preclinical Studies For Nonalcoholic Steatohepatitis (NASH)

SINGAPORE, Oct. 26, 2019 /PRNewswire/ -- HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve quantifiable and reproducible...

2019-10-26 19:00 505

Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences

SAN FRANCISCO and SUZHOU, China, Oct. 26, 2019 /PRNewswire/ -- Adagene, Inc., a clinical stage biotech company with innovative antibody discovery and engineering technologies, announced that it is presenting its lead program at international conferences.  During the Festival of Biologics confere...

2019-10-26 18:01 580

Fountain Medical Development Limited Announces $62 mm Series D Round Financing, Further Strengthening its Global Services Capabilities

BEIJING and SHANGHAI , Oct. 25, 2019 /PRNewswire/ -- Recently, Fountain Medical Development Limited ("Fountain Medical" or "Company") announced its$62 mm Series D round financing. The investment was led by Goldman Sachs, with Lilly Asia Ventures as co-investor. Proceeds of the Series D financing ...

2019-10-25 14:06 1994

/C O R R E C T I O N -- Menarini I.F.R./

In the news release, Nobel Prize Recipient, Louis Ignarro, on Scientific Committee of "Fondazione Internazionale Menarini", issued24-Oct-2019 by Menarini I.F.R. over PR Newswire, we are advised by the company that the second paragraph, 5th sentence, should read "Nitric Oxide Society" rather than ...

2019-10-25 06:28 438

World Federation of Neurology Reveals New Frontiers in Epilepsy Treatment for Children, Pregnant Women and, New Links Between ADHD and Epilepsy at 24th Annual World Congress of Neurology, Dubai, Oct 27 - 31

DUBAI, United Arab Emirates, Oct. 24, 2019 /PRNewswire/ -- World Federation of Neurology -- The road to caring for patients with epilepsy is leading to more effective options for patients of all ages, according to expert findings unveiled by members of the World Federation of Neurology. Breakthro...

2019-10-24 21:00 446

World first clinical trial commenced in alcohol use disorder

MELBOURNE, Australia, Oct. 24, 2019 /PRNewswire/ -- A medication currently used to treat insomnia may also be effective in preventing alcohol intake and relapse in alcohol use disorder, according to researchers at the Florey Institute of Neuroscience and Mental Health. A world-first clinical stu...

2019-10-24 12:01 266

Mundipharma Thailand Recognised as "Best Companies to Work for in Asia" Award

BANGKOK, Oct. 23, 2019 /PRNewswire/ -- Mundipharma was named one of the "Best Companies to Work for inAsia" in Thailand by HR Asia -- the premier publication on human resource professionals in theAsia Pacific. This is the first time Mundipharma Thailand has won the award in the country.

2019-10-23 13:32 349

Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment

PROVIDENCE, Rhode Island, Oct. 23, 2019 /PRNewswire/ -- Announced today, Chugai Pharmaceutical Co., Ltd. ("Chugai"), a member of the Roche Group, will extend the company's licensed access to theImmunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc. ...

2019-10-23 04:10 345

BioGX Receives CE-IVD Mark For Enhanced Flu Assay

AMSTERDAM, Oct. 22, 2019 /PRNewswire/ -- BioGX B.V., the European subsidiary of Birmingham, Alabama based BioGX, announced it has received CE-IVD marking for its new Flu A, Flu B, RSV A/B automated test. The new test significantly enhances the strain coverage and detection sensitivity and offers ...

2019-10-22 20:07 307
123456 ... 100